Clinical Trials Directory

Trials / Completed

CompletedNCT04954885

Evaluating Modifiable Biomarkers for the Prediction of Immunotherapy Response and Toxicity

Status
Completed
Phase
Study type
Observational
Enrollment
2 (actual)
Sponsor
Ohio State University Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This study evaluates gut microbiome and functional status as modifiable biomarkers in predicting immunotherapy response and toxicity in patients with stage IV non-squamous non-small cell lung cancer receiving pembrolizumab alone or in combination with pemetrexed and carboplatin on the INSIGNIA trial. The goal of this study is to estimate the extent to which future interventions that seek to rationally modify the gut microbiome and/or functional status can improve outcomes.

Detailed description

PRIMARY OBJECTIVE: I. To quantify the performance of two modifiable biomarkers -- the microbiome and functional status - to use as predictive and/or prognostic indicators of clinical benefit (overall survival, progression-free survival) in lung cancer patients who receive randomized treatment combinations prescribed by the INSIGNA protocol. SECONDARY OBJECTIVE: I. To quantify the predictive power of two modifiable biomarkers - the microbiome and functional status -- for the development of immune-related adverse events (irAEs). OUTLINE: Patients receive treatment by their treating physician as described in the INSIGNA protocol based on their designated treatment arm. Patients then undergo stool sample collection, complete questionnaires and functional status assessments, such as short physical performance battery over 10 minutes and 6 minute walk test, at baseline, days 40 (cycle 3), day 80 (cycle 5), day 180 (cycle 10) and end of treatment (up to 2 years).

Conditions

Interventions

TypeNameDescription
PROCEDUREBiospecimen CollectionUndergo stool sample
OTHERPhysical Performance TestingUndergo short physical performance battery
OTHERPhysical Performance TestingPerform 6-minute walk test
OTHERQuestionnaire AdministrationComplete questionnaires

Timeline

Start date
2021-05-18
Primary completion
2022-10-12
Completion
2022-10-12
First posted
2021-07-08
Last updated
2025-01-27

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT04954885. Inclusion in this directory is not an endorsement.